Vessi Medical has successfully concluded a Series A financing round, raising a substantial $16.5 million. The investment, led by a global strategic investor alongside ALIVE-Israel HealthTech Fund and Agriline, marks a significant milestone in the advancement of cryotherapy technology for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Transformative Solution for NMIBC
Vessi’s groundbreaking approach offers a minimally invasive alternative to the conventional Transurethral Resection of Bladder Tumor (TURBT), a costly and invasive surgical procedure commonly used as the first-line therapy for NMIBC. This innovative solution targets cancer on the surface of the bladder lining, addressing physical symptoms such as urination difficulties, pain, and hematuria, ultimately improving patients’ quality of life.
Strategic Investment and Vision
The participation of a global strategic investor underscores confidence in Vessi’s achievements and potential. Eyal Kochavi, Founder & CEO of Vessi Medical, expressed enthusiasm for the support received, highlighting its significance amidst challenging times. The funding will fuel Vessi’s research and development efforts, facilitate clinical studies in Israel and the U.S., and aid in regulatory clearance, all pivotal steps towards making their NMIBC treatment widely accessible.
Forward-Thinking Partnerships
ALIVE-Israel HealthTech Fund’s investment reflects a strategic approach to support category technology leaders, emphasizing the importance of superior cryotherapy solutions in treating bladder cancer. Prof. Rafi Beyar, Managing General Partner at ALIVE, emphasized the alignment of Vessi’s mission with their investment strategy, foreseeing positive impacts on patient outcomes and healthcare economics.
Visionary Endorsement
Vincent Tchenguiz, owner of Consensus Business Group and Agriline discretionary beneficiary, lauded Vessi Medical’s innovative cryotherapy as a transformative advancement in cancer care and health economics. His endorsement, coupled with strategic investments from ALIVE and Agriline, signals a strong collaborative effort poised to revolutionize NMIBC treatment and drive healthcare innovation.
About Vessi Medical
Vessi Medical, an Israel-based urology medical device company, specializes in innovative cryospray systems tailored for hollow and humid organs. Their technology offers a promising solution for Non Muscle Invasive Bladder Cancer (NMIBC), supported by notable investors like The Trendlines Group and the Israel Innovation Authority.
TL;DR
- Vessi Medical secures $16.5 million in Series A financing for NMIBC cryotherapy technology.
- Innovative approach provides minimally invasive alternative to standard bladder cancer surgery.
- Global strategic investor, ALIVE-Israel HealthTech Fund, and Agriline join forces in backing Vessi’s mission.
- Investment underscores confidence in Vessi’s potential to revolutionize NMIBC treatment and healthcare standards.
Hi, I’m Oren, founder at BIGINTRO, a content strategy agency that helps B2B companies drive growth. We develop search, social, PR, and content marketing strategies tailored to business goals. I also have a dog named Milo.